Table 1.
Quality Assessment of the 9 Trials Meeting Inclusion Criteria
| Trial, Year | Random Sequence Generation | Allocation Concealment | Blinding of Participants and Personnel | Blinding of Outcome Assessmenta | Incomplete Outcome Data | Selective Reporting |
|---|---|---|---|---|---|---|
| National Lung Screening Trial Research Team et al,5 2011 | L | L | L | L/U | L | L |
| Infante et al,7 2015 | L | U | L | L/U | L | L |
| Wille et al,8 2016 | L | L | L | L/U | L | L |
| Paci et al,19 2017 | L | L | L | L/U | L | L |
| Yang et al,12 2018 | H | H | L | L/U | L | L |
| Doroudi et al,20 20 1 8 | L | U | L | L/U | L | L |
| Pastorino et al,21 2019 | L | L | L | L/U | L | L |
| Becker et al,18 2020 | L | U | L | L/U | L | L |
| de Koning et al," 2020 | L | U | L | L/U | L | L |
H = high risk of bias; L = low risk of bias; U = unclear risk of bias.
a
Risk of bias for all-cause mortality/risk of bias for lung cancer-specific mortality.
Note: Quality was assessed with the Cochrane Risk of Bias Tool.15